Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.

Sepsis and septic shock are key contributors to mortality in critically ill patients and thus prompt recognition and management thereof is central to achieving improved patient outcomes. Early initiation of appropriate antimicrobial therapy constitutes a crucial component of the management strategy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roxanne Rule, Fathima Paruk, Piet Becker, Matthew Neuhoff, Julian Chausse, Mohamed Said
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/01719b4efafa4fd2a45b973071614c29
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01719b4efafa4fd2a45b973071614c29
record_format	dspace
spelling	oai:doaj.org-article:01719b4efafa4fd2a45b973071614c292021-12-02T20:09:19ZClinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.1932-620310.1371/journal.pone.0254389https://doaj.org/article/01719b4efafa4fd2a45b973071614c292021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254389https://doaj.org/toc/1932-6203Sepsis and septic shock are key contributors to mortality in critically ill patients and thus prompt recognition and management thereof is central to achieving improved patient outcomes. Early initiation of appropriate antimicrobial therapy constitutes a crucial component of the management strategy and thus early identification of the causative pathogen is essential in informing antimicrobial therapeutic choices. The BioFire FilmArray blood culture identification (BCID) panel is a US Food and Drug Administration (FDA) approved rapid, multiplex polymerase chain reaction assay for use on positive blood cultures. This study evaluated its clinical utility in the intensive care unit (ICU) setting, in terms of amendment of empiric antimicrobial therapy in critically ill patients with sepsis. The assay proved useful in this setting as final results were made available to clinicians significantly earlier than with conventional culture methods. This, in turn, allowed for modification of empirical antimicrobial therapy to more appropriate agents in 32% of patients. Additionally, the use of the BioFire FilmArray BCID panel permitted the prompt implementation of additional infection prevention and control practices in a sizeable proportion (14%) of patients in the study who were harbouring multidrug resistant pathogens. These findings support the use of the BioFire FilmArray BCID panel as a valuable adjunct to conventional culture methods for the diagnosis and subsequent management of critically ill patients with sepsis.Roxanne RuleFathima ParukPiet BeckerMatthew NeuhoffJulian ChausseMohamed SaidPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254389 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Roxanne Rule Fathima Paruk Piet Becker Matthew Neuhoff Julian Chausse Mohamed Said Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
description	Sepsis and septic shock are key contributors to mortality in critically ill patients and thus prompt recognition and management thereof is central to achieving improved patient outcomes. Early initiation of appropriate antimicrobial therapy constitutes a crucial component of the management strategy and thus early identification of the causative pathogen is essential in informing antimicrobial therapeutic choices. The BioFire FilmArray blood culture identification (BCID) panel is a US Food and Drug Administration (FDA) approved rapid, multiplex polymerase chain reaction assay for use on positive blood cultures. This study evaluated its clinical utility in the intensive care unit (ICU) setting, in terms of amendment of empiric antimicrobial therapy in critically ill patients with sepsis. The assay proved useful in this setting as final results were made available to clinicians significantly earlier than with conventional culture methods. This, in turn, allowed for modification of empirical antimicrobial therapy to more appropriate agents in 32% of patients. Additionally, the use of the BioFire FilmArray BCID panel permitted the prompt implementation of additional infection prevention and control practices in a sizeable proportion (14%) of patients in the study who were harbouring multidrug resistant pathogens. These findings support the use of the BioFire FilmArray BCID panel as a valuable adjunct to conventional culture methods for the diagnosis and subsequent management of critically ill patients with sepsis.
format	article
author	Roxanne Rule Fathima Paruk Piet Becker Matthew Neuhoff Julian Chausse Mohamed Said
author_facet	Roxanne Rule Fathima Paruk Piet Becker Matthew Neuhoff Julian Chausse Mohamed Said
author_sort	Roxanne Rule
title	Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
title_short	Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
title_full	Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
title_fullStr	Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
title_full_unstemmed	Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
title_sort	clinical utility of the biofire filmarray blood culture identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/01719b4efafa4fd2a45b973071614c29
work_keys_str_mv	AT roxannerule clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient AT fathimaparuk clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient AT pietbecker clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient AT matthewneuhoff clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient AT julianchausse clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient AT mohamedsaid clinicalutilityofthebiofirefilmarraybloodcultureidentificationpanelintheadjustmentofempiricantimicrobialtherapyinthecriticallyillsepticpatient
_version_	1718375041705443328

Clinical utility of the BioFire FilmArray Blood Culture Identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient.

Ejemplares similares